Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

Trial Profile

Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GELTAMO
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2018 Long term results presented at the 23rd Congress of the European Haematology Association.
    • 06 Dec 2016 Results assessing efficacy and safety from phase II portion of the study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top